Biohaven (NYSE:BHVN) Raised to Strong-Buy at Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of Biohaven (NYSE:BHVN - Free Report) to a strong-buy rating in a research report report published on Tuesday, May 13th,Zacks.com reports. Cantor Fitzgerald also issued estimates for Biohaven's FY2025 earnings at ($6.80) EPS.

BHVN has been the topic of a number of other reports. William Blair upgraded Biohaven to a "strong-buy" rating in a research note on Thursday, April 24th. Robert W. Baird reduced their target price on Biohaven from $60.00 to $57.00 and set an "outperform" rating on the stock in a report on Monday, April 28th. Royal Bank of Canada dropped their price objective on shares of Biohaven from $61.00 to $54.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 13th. JPMorgan Chase & Co. dropped their target price on shares of Biohaven from $72.00 to $68.00 and set an "overweight" rating on the stock in a research note on Wednesday, March 5th. Finally, HC Wainwright restated a "buy" rating and set a $54.00 target price on shares of Biohaven in a research note on Tuesday, March 4th. One research analyst has rated the stock with a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $59.46.

Biohaven Stock Performance

Shares of BHVN stock traded down $0.19 during mid-day trading on Tuesday, hitting $15.56. The company's stock had a trading volume of 494,271 shares, compared to its average volume of 1,477,516. The company has a market cap of $1.59 billion, a PE ratio of -1.66 and a beta of 1.18. The company's fifty day simple moving average is $22.03 and its 200-day simple moving average is $33.85. Biohaven has a 52 week low of $14.69 and a 52 week high of $55.70.

Biohaven (NYSE:BHVN - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($2.17) EPS for the quarter, missing the consensus estimate of ($1.67) by ($0.50). On average, equities analysts anticipate that Biohaven will post -8.9 earnings per share for the current year.

Insider Buying and Selling at Biohaven

In other Biohaven news, Director John W. Childs acquired 32,700 shares of the firm's stock in a transaction on Tuesday, March 4th. The stock was acquired at an average cost of $30.47 per share, for a total transaction of $996,369.00. Following the purchase, the director now owns 2,320,571 shares in the company, valued at approximately $70,707,798.37. The trade was a 1.43% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 16.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Barclays PLC grew its position in Biohaven by 87.6% during the third quarter. Barclays PLC now owns 268,077 shares of the company's stock valued at $13,396,000 after buying an additional 125,189 shares during the period. ARS Investment Partners LLC grew its position in shares of Biohaven by 1.0% during the 4th quarter. ARS Investment Partners LLC now owns 1,040,712 shares of the company's stock valued at $38,871,000 after acquiring an additional 10,473 shares during the period. Inspire Investing LLC grew its position in shares of Biohaven by 32.9% during the 4th quarter. Inspire Investing LLC now owns 10,895 shares of the company's stock valued at $407,000 after acquiring an additional 2,698 shares during the period. KBC Group NV increased its stake in shares of Biohaven by 50.1% in the 4th quarter. KBC Group NV now owns 3,377 shares of the company's stock valued at $126,000 after purchasing an additional 1,127 shares in the last quarter. Finally, FSC Wealth Advisors LLC raised its holdings in Biohaven by 3.3% in the 4th quarter. FSC Wealth Advisors LLC now owns 15,500 shares of the company's stock worth $579,000 after purchasing an additional 500 shares during the period. Hedge funds and other institutional investors own 88.78% of the company's stock.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.